DGAP-News: Adrenomed AG
/ Key word(s): Personnel
Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer
Hennigsdorf/Berlin (Germany), June 23, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. med. Steffen Stürzebecher as Chief Medical Officer (CMO) of Adrenomed, effective June 20, 2022. Dr. Stürzebecher is a board-certified pharmacologist with extensive clinical development experience in pivotal Phase III trials and regulatory submissions as well as in early-stage development of innovative treatment options. Dr. med. Jens Zimmermann and Dr. Stürzebecher have been working jointly for the past two months on further substantiating Adrenomed’s regulatory strategy and design of their upcoming pivotal trial. Dr. Zimmermann will retire after serving as Adrenomed’s CMO since December 2017 and member of the Executive Board.
Dr. Richard Jones, CEO of Adrenomed, said: “We are excited to have Steffen Stürzebecher on board to lead Adrenomed’s clinical development activities. Benefiting from his extensive experience and competencies to successfully drive clinical and medical developments, he will advance the pivotal program for our antibody enibarcimab to treat the loss of vascular integrity in sepsis and septic shock. While we warmly welcome Steffen to his new role, we are sad to see Jens leave. I would like to express my sincerest thanks for his outstanding work and dedication to the Company. His years at Adrenomed were highlighted by the successful proof-of-concept trial AdrenOSS-2, which investigated the safety, tolerability, and efficacy of enibarcimab and paved the way for our further developmental program.”
Dr. Jens Zimmermann, CMO emeritus of Adrenomed, commented: “After more than four years at Adrenomed I will be stepping down as Chief Medical Officer due to health reasons. During this exciting and exceptional time, I have had the opportunity to contribute to the development of enibarcimab, a promising potential treatment option in sepsis and septic shock. Now the time has come to pass the baton on to my successor. I wish Steffen and the entire team much success for their work joined with the hope that sepsis patients will benefit from enibarcimab in the future!”
Dr. Steffen Stürzebecher, CMO of Adrenomed, added: “Adrenomed’s mission is clear: Sepsis is a major public health threat and for the advanced disease stage of septic shock there is a definite lack of effective treatments. Our promising trial program around enibarcimab is designed to help bridge this gap. I very much look forward to working with the experienced Adrenomed team on advancing enibarcimab’s late-stage clinical development and I am fully committed to the challenge of providing a new treatment option for critically ill patients.”
Dr. Stürzebecher previously held several executive positions at Grünenthal, including Chief Medical Officer, Head R&D Portfolio Management, Head of Global Development, and Head of Global Medical Sciences. His former management experiences include the role of President Clinical R&D / Chief Medical Officer at Glenmark Pharmaceuticals and most recently as the CMO of Eisbach Bio GmbH. At Schering AG, he held the positions of Head of Global Pharmacogenomics, Biomarker Development and Non-Clinical Statistics and Head of Clinical Development Cardiovascular and Central Nervous System. He received his doctorate in medicine (Dr. med.) from the Faculty of Medicine at Freie Universität Berlin.
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab (INN: enibarcimab) is a first-in-class non-blocking monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock. For further information, please visit www.adrenomed.com and follow us on LinkedIn and Twitter.
23.06.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.